This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BOLD Boundless Bio (BOLD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Boundless Bio Stock (NASDAQ:BOLD) 30 days 90 days 365 days Advanced Chart Get Boundless Bio alerts:Sign Up Key Stats Today's Range$2.36▼$2.5850-Day Range$59.97▼$59.9752-Week Range$1.00▼$4.72Volume96,520 shsAverage Volume101,202 shsMarket Capitalization$23.62 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California. Read More Boundless Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreBOLD MarketRank™: Boundless Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 566th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingBoundless Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageBoundless Bio has only been the subject of 3 research reports in the past 90 days.Read more about Boundless Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Boundless Bio are expected to grow in the coming year, from ($3.85) to ($3.35) per share.Price to Book Value per Share RatioBoundless Bio has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.91% of the float of Boundless Bio has been sold short.Short Interest Ratio / Days to CoverBoundless Bio has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Boundless Bio has recently increased by 21.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoundless Bio does not currently pay a dividend.Dividend GrowthBoundless Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.91% of the float of Boundless Bio has been sold short.Short Interest Ratio / Days to CoverBoundless Bio has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Boundless Bio has recently increased by 21.21%, indicating that investor sentiment is decreasing significantly. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Boundless Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Boundless Bio's insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boundless Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLD Stock News HeadlinesBoundless Bio Inc News (BOLD) - Investing.comJune 26, 2025 | investing.comBoundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 5, 2025 | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 6 at 2:00 AM | Brownstone Research (Ad)HC Wainwright & Co. Initiates Coverage of Boundless Bio (BOLD) with Buy RecommendationJune 2, 2025 | msn.comLeerink Partners Downgrades Boundless Bio (BOLD)May 29, 2025 | msn.comLeerink Partners Downgrades Boundless Bio (BOLD)May 29, 2025 | msn.comBoundless Bio Announces Portfolio Prioritization and Runway ExtensionMay 23, 2025 | globenewswire.comBoundless Bio Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | globenewswire.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How were Boundless Bio's earnings last quarter? Boundless Bio, Inc. (NASDAQ:BOLD) released its quarterly earnings results on Friday, May, 9th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.03. When did Boundless Bio IPO? Boundless Bio (BOLD) raised $100 million in an IPO on Thursday, March 28th 2024. The company issued 6,250,000 shares at $16.00 per share. What other stocks do shareholders of Boundless Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boundless Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings5/09/2025Today7/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED-BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:BOLD CIK1628738 Webwww.audentestx.com Phone415-818-1001FaxN/AEmployees207Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+279.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.60% Return on Assets-34.53% Debt Debt-to-Equity Ratio0.35 Current Ratio22.15 Quick Ratio22.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book0.16Miscellaneous Outstanding Shares22,390,000Free Float17,663,000Market Cap$23.62 million OptionableNo Data Beta-1.34 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BOLD) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boundless Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Boundless Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.